Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
[HTML][HTML] Screening for epidermal growth factor receptor mutations in lung cancer
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
[HTML][HTML] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of …
…, VA Miller, I Petersen, V Roggli, R Rosell… - Journal of thoracic …, 2011 - Elsevier
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2
…, V Miller, C Manegold, G Scagliotti, R Rosell… - Journal of Clinical …, 2004 - ascopubs.org
Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
…, TJ Boggon, PC Ma, C Costa, M Taron, R Rosell… - Nature …, 2012 - nature.com
Human non–small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently
respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, …
respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, …
Non-small-cell lung cancer
…, T Mok, F Petrella, L Spaggiari, R Rosell - Nature reviews Disease …, 2015 - nature.com
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous class …
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous class …
[PDF][PDF] Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non–small-cell lung cancer patients …
…, B Massuti, M Sanchez-Ronco, R Rosell - Journal of clinical …, 2007 - academia.edu
… Address reprint requests to Rafael Rosell, MD, Chief, Medical Oncology … Rosell R,
Lopez-Cabrerizo MP, Astudillo J: Preoperative chemotherapy for stage IIIA non-small cell lung …
Lopez-Cabrerizo MP, Astudillo J: Preoperative chemotherapy for stage IIIA non-small cell lung …
[HTML][HTML] Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
…, RJ Stephens, A Dunant, V Torri, R Rosell… - Database of Abstracts …, 2008 - ncbi.nlm.nih.gov
This meta-analysis of individual patient data concluded that postoperative cisplatin-based
chemotherapy significantly improved survival compared with no chemotherapy in patients with …
chemotherapy significantly improved survival compared with no chemotherapy in patients with …
Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1
…, C Manegold, G Scagliotti, R Rosell… - Journal of Clinical …, 2004 - ascopubs.org
Purpose The purpose of this study was to determine whether the addition of the epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
[HTML][HTML] Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
…, M Pérol, R Dziadziuszko, R Rosell… - … England Journal of …, 2017 - Mass Medical Soc
Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …